Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode

February 25, 2026 00:55:05
Episode Cover

2025: A Year in Review

Each year, hundreds of articles are published that pertain to the resuscitation and care of critically ill emergency department patients. In this podcast, we...

Listen

Episode 0

April 27, 2020 00:22:04
Episode Cover

Vasopressors & The Older Patient - The 65 Trial

Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic...

Listen

Episode 0

December 11, 2019 00:20:17
Episode Cover

Amniotic Fluid Embolism

Amniotic fluid embolism (AFE) is a catastrophic syndrome that occurs very soon after delivery and is a significant cause of morbidity and mortality.  Unfortunately,...

Listen